COVID-19 Vaccine Comparison

Pfizer-BioNTech 
Comirnaty™ 
5-11 Years

Pfizer-BioNTech 
Comirnaty™ 
≥12 Years

AstraZeneca Vaxzevria™  

Janssen 
(Johnson & Johnson)

Multi-dose preservative-free vials containing 10 doses

Cartons of 10 or 195 vials

Orange cap; orange border on vial

Multi-dose preservative-free vials containing 6^a doses

Cartons of 25 and 195 vials

Purple cap; purple border on vial (may not yet be on existing inventory)

Multi-dose preservative-free vials containing maximum 20 doses depending on volume of dose being administered

Cartons of 10 vials

US-labelled product available in vials containing 14 (maximum 15) 0.5 mL doses^b

Multi-dose preservative-free available in:
8 dose vial (4 ml) 
10 dose vial (5 ml)

Store at -90°C to -60°C (ultrafreezer) for up to 6 months from date on label.

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.

Store at -90°C to -60°C^c (ultrafreezer) until the expiry date printed on the label.^d

Store and/or transport at -25°C to -15°C for up to 2 weeks.^e 

Thaw undiluted product in fridge (takes up to 4 hours).
or
Thaw undiluted product at room temperature (takes ~30 minutes).

Do not refreeze thawed vials.

Thaw undiluted product in fridge (takes up to 3 hours).
or
Thaw undiluted product at room temperature (takes ~30 minutes).

Do not refreeze thawed vials.

Not required 

Do not freeze.

Thaw over night in fridge
or
Thaw at room temperature up to 25°C (single vial takes ~1 hour; carton of 10 vials takes ~4 hours).

Do not refreeze thawed vials. 

Undiluted product: up to 10 weeks

Undiluted product: up to 31 days

Thawed, undiluted product can be transported at 2°C to 8°C for up to 12 hours but this counts against the 31-day limit.

Store at 2° to 8°C.

Expiry date found on vial label and refers to last day of that month.

Up to 6 months, not exceeding original expiry date (EXP).

Expiry date of vaccine should be checked and manually written on carton. See Product Monograph for additional details about expiry dates.

See here for EU English-only labelled product.

Dilute thawed vials once they have reached room temperature with 1.3 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilute thawed vials once they have reached room temperature with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilution/
reconstitution not required

Prior to dilution, no more than 12 hours

After dilution, use within 12 hours from time of dilution.^g  

(Time is additive: up to 24 hours at room temperature)

Prior to dilution, no more than 2 hours (including thaw time)

After dilution, use within 6 hours from time of dilution.

(Time is additive: up to 8 hours at room temperature)

Store in a refrigerator (2°C to 8°C). 

No stability data of unopened vial at room temperature. See stability after 1st puncture.  

Up to 24 hours  at 2°C to 25°C

Do not puncture and withdraw doses more than 20 times.^h

Up to 6 hours at room temperature (up to 25°C)

Up to 48 hours when refrigerated (2°C to 8°C)

Product can be returned to the fridge but the cumulative time at room temperature must not exceed 6 hours and cumulative storage once opened must not exceed 48 hours.

Up to 3 hours at room temperature (up to 25°C)

Up to 6 hours at 2°C to 8°C

Yes.
Store in original carton.

Yes.
Store in original carton.

Yes.
Store in original carton.

Invert gently during reconstitution.
Do not shake.

Invert gently during reconstitution.
Do not shake.

Swirl vial gently after thawing and between each withdrawal.
Do not shake.

None specified. Product is a solution.

Swirl gently upright for 10 seconds.
Do not shake.

BEFORE dilution: thawed suspension may be white to off-white; may contain opaque amorphous particles.

AFTER dilution: white to off-white suspension; ensure no particulate matter/discolouration.

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: off-white suspension; ensure no particulate matter/ discolouration.

White to off-white dispersion—may contain white or translucent product-related particles; ensure no foreign particulate matter or discolouration.

Colourless to slightly brown, clear to slightly opaque solution; ensure no foreign particulate matter or discolouration.

Colourless to slightly yellow, clear to very opalescent suspension; ensure no foreign particulate matter or discolouration.

0.5 mL

2^i,j

28 days

4 to 12 weeks

a. Packaging originally indicated 5 doses per vial though this has been updated to 6 doses per vial to minimize waste and increase access. Six doses can be achieved by using low dead-volume syringes and/or needles. If standard syringes and needles are used, there may not be sufficient volume to extract 6 full doses from a single vial.

b. Moderna Tx, Inc. is providing US-labelled vaccine supplies in order to expedite the distribution of the vaccine in Canada. The contents are identical to the Canadian-labelled product. However, important differences in packaging and labelling include:

• Vials contain 8 mL providing 14 doses (US label maximum 15 doses) of 0.5 mL and are supplied in cartons of 10 vials
• English-only labels
• Important Canadian-specific information absent from labels (e.g. DIN)
• Expiration dates are not printed on vial and carton labels

Continue to use the Canadian product monograph. For access to expiration dates, Canadian-specific labelling information and further details, see the Health Canada MedEffect notice.

c. On August 27, 2021, Health Canada expanded the Ultra Low Temperature storage conditions to now allow storage at -90°C to -60°C (-130°F to -76°F) versus the previously approved -80°C to -60°C (-112°F to -76°F). All references to storage conditions of -80°C to -60°C (-112°F to -76°F) on cartons and supporting printed material currently in Canada should now be considered between -90°C to -60°C (-130°F to -76°F.

d. On August 27, 2021, Health Canada authorized an update to the Pfizer-BioNTech Comirnaty™ Product Monograph to allow a 3-month extension to the expiry date for Pfizer-BioNTech Comirnaty™ ≥12 years product only (not pediatric product) vials with expiry dates of August 2021 through February 2022 printed on the vial and carton labels. Cartons and vials of Pfizer-BioNTech Comirnaty™ with an expiry date of August 2021 through February 2022 printed on the label may remain in use for 3 months beyond the printed date as long as all approved storage conditions have been maintained.

e. Vials stored/transported at -25°C to -15°C for up to 2 weeks may be returned (once) to the recommended storage condition of -80°C to -60°C. Total time the vials are stored and /or transported at -25°C to -15°C should be tracked and not exceed 2 weeks.

f. Health Canada has authorized a 2-month shelf life extension (from 7 months to 9 months) for certain lots of the SPIKEVAX (previously COVID-19 Moderna vaccine). This extension applies to lots of US-labelled vaccine supplies with English-only vial and carton labels. See affected lots at the Health Canada Communication.

g. Vial labels and cartons may state that a vial should be discarded 6 hours after dilution; however, additional testing has been completed to support 12 hours of stability after dilution.

h. As per Health Canada Distribution of SPIKEVAX (elasomeran) COVID-19 Vaccine with English-only Vial and Carton Labels, Nov 10, 2021

i. See information about additional doses for moderately to severely immunocompromised individuals and recommendations for booster doses here. 

j.  Individuals who received two doses of AstraZeneca Vaxzevria™ as a primary series are eligible to receive an mRNA vaccine (Pfizer-BioNTech Comirnaty™ or Moderna Spikevax™) booster dose 5 months or later after completion of their primary series. AstraZeneca Vaxzevria™ (only available through Public Health) may be given to those for whom there is a contraindication to an mRNA vaccine.

k. Janssen (Johnson & Johnson) single dose vaccine recipients are eligible for a booster dose with an mRNA vaccine 2 months or later following their vaccination. 

l. There is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness. Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a second dose for earlier protection should be considered when deciding the interval. People who completed their primary vaccine series using manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

References

• Product Monographs
  • Comirnaty™
  • Spikevax™
  • Vaxzevria™
  • Janssen COVID-19 Vaccine
• NACI
  • Recommendations on the use of COVID-19 vaccines; 22 Oct 2021
  • Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age; 19 Nov 2021
• eHealth COVID-19 Immunization Manual
  • COVID-19 Vaccine Contraindications and Precautions Background Document 20 Dec 2021
•  SHA
  • CV-19 G0111 COVID-19 Vaccine Comparison Table available in General Vaccine Information
• SIM
  • Chapter 10: Biological Products

Last updated

09 Dec 2021